C. Blake Gilks

Department of Pathology and Laboratory Medicine
Faculty of Medicine
Professor since July 2005

BSc (University of New Brunswick 1975-78)
M.D. cum laude Medicine (Dalhousie University 1978-82)
Rotating Internship (Royal Columbian Hospital 1982-83)
Resident Anatomic Pathology (University of British Columbia 1985-88)
Fellow Pathology (Harvard University 1988)
Fellow Pathology (Fox Chase Cancer Centre, Philadelphia 1989-91)

Fellow of the Royal College of Physicians and Surgeons of Canada (Anatomical Pathology)

Mel Bernstein Award for Resident Teaching, 1994 Roberta Miller Award for “Outstanding Professional Role Model”, Pathology and Lab Medicine Residency Program, 1998

SELECTED PUBLICATIONS

(a) Journals

1. Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. (2009-10-10). Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 0(0),0
2. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB. (2009-10-02). MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 4(10),7314
3. Jensen KC, Nielsen TO, Gilks CB, West RB. (2009-09-09). HER2 Intermediate Breast Cancers. Am J Surg Pathol. 0(0),0
4. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB. (2009-09-04). A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol. 0(0),0
5. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. (2009-07-29). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 4(7),6412
6. Gilks CB, Prat J. (2009-06-24). Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 40(9),1213
7. Shah SP, Koebel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. (2009-06-10). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 360(26),2719
8. Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V. (2009-06-01). Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res. 69(11),4843
9. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S. (2009-05-29). Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer. 9(0),165
10. Espinosa I, Beck AH, Lee CH, Zhu S, Montgomery KD, Marinelli RJ, Ganjoo KN, Nielsen TO, Gilks CB, West RB, van de Rijn M. (2009-05-14). Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. Am J Pathol. 174(6),2347
11. Terry J, Torlakovic EE, Garratt J, Miller D, Köbel M, Cooper J, Bahzad S, Pilavdzic D, Oʼmalley F, Oʼbrien AE, Sengupta S, Alport E, Têtu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB. (2009-04-09). Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol. 0(0),0
12. Köbel M, Gilks CB, Huntsman DG. (2009-03-12). Dicer and Drosha in ovarian cancer. N Engl J Med. 360(11),1150
13. Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, Laskin J. (2009-02-23). BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer. J Thorac Oncol. 4(4),486
14. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. (2009-02-01). The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 19(1),58
15. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. (2009-01-09). IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 22(3),469
16. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. (2009-01-01). A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. Am J Surg Pathol. 33(1),14
17. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. (2008-12-05). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 22(3),393
18. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. (2008-12-02). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12),232
19. Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ. (2008-12-01). Endocervical Adenocarcinomas With Ovarian Metastases: Analysis of 29 Cases With Emphasis on Minimally Invasive Cervical Tumors and the Ability of the Metastases to Simulate Primary Ovarian Neoplasms. Am J Surg Pathol. 32(12),1835
20. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. (2008-11-10). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. J Clin Oncol. 26(35),5697
21. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH. (2008-10-15). Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 3(10),3409
22. Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K. (2008-10-01). Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. Pathology. 40(6),611
23. Jensen KC, Schaeffer DF, Cheang M, Montgomery K, West RB, Gilks CB, Ross D, Turashvili G, Schnitt S, van de Rijn M. (2008-09-26). Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. Mod Pathol. 21(12),1413
24. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. (2008-09-01). Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 110(3),408
25. Woo MM, Salamanca CM, Symowicz J, Stack MS, Miller DM, Leung PC, Gilks CB, Auersperg N. (2008-08-03). SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. Gynecol Oncol. 111(1),125
26. Köbel M, Huntsman D, Gilks CB. (2008-08-01). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 22(0),10
27. Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. (2008-08-01). Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 39(8),1239
28. Auersperg N, Woo MM, Gilks CB. (2008-07-07). The origin of ovarian carcinomas: A developmental view. Gynecol Oncol. 110(3),452
29. Han G, Gilks CB, Leung S, Ewanowich CA, Irving JA, Longacre TA, Soslow RA. (2008-07-01). Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma: An Interobserver Correlative and Immunohistochemical Study of 32 Cases. Am J Surg Pathol. 32(7),955
30. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ. (2008-06-10). Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 110(2),256
31. Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. (2008-06-01). Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 47(6),481
32. Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S. (2008-04-24). Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch. 452(6),589
33. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. (2008-04-14). The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 88(6),591
34. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, van de Rijn M. (2008-03-01). Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 14(5),1423
35. Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, Oliveira C, Ehlen TG, Gilks CB, Huntsman D, Auersperg N. (2008-01-23). Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. Int J Gynecol Cancer. 18(6),1234
36. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. (2008-01-22). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 8(17),0
37. Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB. (2008-01-09). New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 112(3),453
38. Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. (2007-11-15). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med. 5(1),33
39. Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG. (2007-10-03). Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 110(3),417
40. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N. (2007-09-01). HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci. 14(6),605
41. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. (2007-08-24). Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol. 20(11),1156
42. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. (2007-08-01). Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 142(8),717
43. Cupp JS, Miller MA, Montgomery KD, Nielsen TO, Oʼconnell JX, Huntsman D, Rijn MV, Gilks CB, West RB. (2007-06-01). Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides. Am J Surg Pathol. 31(6),970
44. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. (2007-03-13). Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 107(2),249
45. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. (2007-02-01). Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 14(2),719
46. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J, Wood-Baker R, Gown AM. (2007-01-01). Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation-An Entity of No Clinical or Prognostic Significance. Am J Surg Pathol. 31(1),26
47. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. (2006-12-20). Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. J Clin Oncol. 24(36),5637
48. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. (2006-11-24). Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 20(1),84
49. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M. (2006-11-01). Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 24(31),5079
50. Masoudi H, Van Niekerk DJ, Gilks CB, Cheang M, Bilek K, Fischer U, Ehlen T, Miller D, Horn LC. (2006-11-01). Loss of p16 INK4 expression in invasive squamous cell carcinoma of the uterine cervix is an adverse prognostic marker. Histopathology 49(5),542
51. Choi JH, Gilks CB, Auersperg N, Leung PC. (2006-09-05). Immunolocalization of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Type-I GnRH Receptor during Follicular Development in the Human Ovary. J Clin Endocrinol Metab. 91(11),4562
52. Tsui-Lien Mao, MDabce, Chih-Yi Hsu, MDf, May J. Yen, MDabc, Blake Gilks, MDd, Jim Jinn-Chyuan Sheu, PhDabc, Edward Gabrielson, MDabc, Russell Vang, MDabc, Leslie Cope, PhDabc, Robert J. Kurman, MDabc, Tian-Li Wang, PhDabc, Ie-Ming Shih, MD, PhD (2006-09-01). Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma Hum Pathol. 37(9),1169
53. Tse GM, Tan PH, Lui PC, Gilks B, Poon CS, Ma TK, Law BK, Lam WW. (2006-05-12). The role of immunohistochemistry for smooth muscle actin, p63, CD10 and CK 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol. 60(3),315
54. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. (2006-05-01). Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 191(5),581
55. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE. (2006-05-01). Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 66(9),4872
56. Ota T, Choi KB, Gilks CB, Leung PC, Auersperg N. (2006-02-01). Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. Differentiation. 74(1),1
57. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. (2006-01-17). A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103(3),690
58. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. (2006-01-01). MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathology 19(1),69
59. Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK. (2005-11-01). CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol. 58(11),1185
60. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. (2005-11-01). An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 85(11),1392
61. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. (2005-10-19). Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecologic Oncology 100(2),264
62. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. (2005-08-01). Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7(5),796
63. Martin JD, Gilks B, Lim P. (2005-08-01). Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. Gynecol Oncol. 98(2),299
64. Prentice LM, Shadeo A, Lestou VS, Miller MA, Deleeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG. (2005-07-18). NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 24(49),7281
65. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB. (2005-07-01). Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol. 24(3),205
66. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. (2005-06-16). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 24(26),4281
67. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. (2005-05-01). Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9),1770
68. Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. (2005-04-01). Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 24(2),147
69. Stone JE, Parker R, Gilks CB, Stanbridge EJ, Liao SY, Aquino-Parsons C. (2005-04-01). Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis. Eur J Gynaecol Oncol. 26(1),31
70. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. (2005-03-01). Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 96(3),684
71. Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, Miller D, Gilks CB. (2005-03-01). Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 29(3),295
72. Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM. (2005-03-01). Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 29(3),281
73. Woo MM, Alkushi A, Verhage HG, Magliocco AM, Leung PC, Gilks CB, Auersperg N. (2004-12-01). Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. Clinical Cancer Research 10(23),7958
74. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. (2004-10-28). Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncology 96(1),48
75. Avedis Kazanjian A, Wallis-Schultz D, Au N, Nigam R, Venken K, Cagle PT, DickeyBF, Bellen HJ, Gilks CB, Grimes L. (2004-10-01). Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells Cancer Research 64(19),6874
76. Au NHC, Gown A, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12(3),240
77. Au NHC, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliot WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers J of Pathology (UK) 204(1),101
78. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hernandez-Boussard T, Cowan D, Dressler L, Livasy C, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. (2004-08-15). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 10(16),5367
79. Somasiri A, Nielsen J, Makretsov N, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, and Roskelley CD. (2004-08-01). Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression Cancer Research 64(15),5068
80. Makretsov N, Huntsman D, Nielsen T, Yorida E, Peacock M, Cheang M, Sandra E.Dunn, Hayes M, Matt van de Rijn, Bajdik C, and Gilks B. (2004-08-01). Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Cancer Clinical Cancer Research 10(18),6143
81. Dabiri SH, Huntsman DG, Makretsov N, Cheang M, Gilks CB, Bajdik C, Gelmon KA, Chia S, Hayes MM. (2004-06-15). The presence of stromal mast cells identifies a subset of invasive breast cancers with a favourable prognosis. Mod Pathol 17(6),690
82. Woo MM, Gilks CB, Verhage HG, Longacre TA, Leung PCK, Auersperg N. (2004-05-01). Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts Gynecologic Oncology 93(2),315
83. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. (2004-04-01). Interpretation of p53 immunohistochemical staining in endometrial carcinoma: establishing a clinically relevant cut-off. Int J Gynecol Pathol 23(2),129
84. van de Rijn M, Gilks CB. (2004-02-01). Applications of microarrays to histopathology. Histopathology 44(1),97
85. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB,Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE (2004-01-01). Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival Cancer Research 64(1),286
86. Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, Nielsen TO, Rubin BP, Patel R, Goldblum JR, Siegmund D, Botstein D, Brown PO, Gilks CB, and van de Rijn M. (2003-12-10). Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163(6),2383
87. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin S-F, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Yu DS, Vnkitaraman A, Ponder B, Doherty A, Aparicio S, (2003-11-26). EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5),523
88. Makretsov N, Gilks CB, Coldman AJ, Hayes M, and Huntsman D. (2003-10-15). Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 34(10),1001
89. Nielsen TO, Hsu FD, O'Connell JX, Gilks CB, Sorensen PHB, Linn SC, West RB, Liu CL, Botstein D, Brown PO, van de Rijn M (2003-10-01). Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology American Journal of Pathology 163(4),1449
90. Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB. (2003-03-01). Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442(3),271
91. Gilks CB, Alkushi A, Yue JJ, Lanvin D, Ehlen TG, Miller DM. (2003-01-01). Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol. 22(1),29
92. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M, Gilks CB. (2002-12-15). Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 15(12),1374
93. Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, and van de Rijn M. (2002-11-15). Software tools for high-throughput analysis and archiving of immunohisothemistry staining data obtained with tissue microarrays. Am J Pathol 161(5),1557
94. Irving JA, Dupuis B, Wang L, Gilks CB. (2002-07-01). Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium Fertil Steril. 78(1),195
95. Poon KS, Gilks CB, Masterson JS. (2002-06-01). Metastatic Crohn's disease involving the genitalia. J Urol. 167(6),2541
96. Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB. (2002-04-05). Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 15(4),365
97. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, and Gilks CB. (2002-03-01). Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 117(0),723

(b) Chapters

Invited contributor to Pathology and Genetics of Tumors of the Breast and Female Genital Organs (F. Tavassoli and M. Stratton, editors) in the World Health Organization series on histopathological and genetic criteria for classification of tumors. IARC Press. 2003